You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma
  1. Jeremy Allan Goldfarb1,
  2. Renata Ferrarotto2,
  3. Neil Gross3,
  4. Ryan Goepfert3,
  5. James Matthew Debnam4,
  6. Brandon Gunn5,
  7. Priyadharsini Nagarajan6,
  8. Bita Esmaeli1
  1. 1 Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2 Department of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  3. 3 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  4. 4 Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  5. 5 Department of Radiation Oncology, The University of Texas MD Anderson Division of Radiation Oncology, Houston, Texas, USA
  6. 6 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  1. Correspondence to Dr Bita Esmaeli, Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; besmaeli{at}mdanderson.org

Abstract

Purpose To report on the outcomes of immunotherapy in patients with locally advanced periorbital squamous cell carcinoma.

Methods We performed a retrospective chart review of seven consecutive patients with locally advanced periorbital cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy. Treatments and therapeutic outcomes were reviewed.

Results Of the seven patients, six were treated with cemiplimab, and one was treated with pembrolizumab. Five patients were treated with immunotherapy as neoadjuvant therapy before planned surgical resection; two patients received immunotherapy for treatment of advanced recurrent lesions deemed unresectable following multiple previous excisions and radiation therapy. In all seven patients, measurable clinical and/or radiologic response was observed.

Conclusions Our findings support the emerging role of anti-PD-1 immunotherapy in the management of locally advanced periorbital cutaneous squamous cell carcinoma.

  • eye lids
  • neoplasia
  • orbit
  • pathology
  • treatment medical

Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information. Additional data, if required, is available by contacting the corresponding author.

http://dx.doi.org/10.1136/bjophthalmol-2021-319417

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplemental information. Additional data, if required, is available by contacting the corresponding author.

    View Full Text

    Footnotes

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • Highlights from this issue
      At a glance
      Frank Larkin
      British Journal of Ophthalmology 2023; 107 i-ii Published Online First: 20 Feb 2023. doi: 10.1136/bjo-2023-323354